These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 16034146

  • 1. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.
    J Immunol; 2005 Aug 01; 175(3):2010-7. PubMed ID: 16034146
    [Abstract] [Full Text] [Related]

  • 2. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
    Piriou ER, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D.
    Eur J Immunol; 2005 Mar 01; 35(3):796-805. PubMed ID: 15724243
    [Abstract] [Full Text] [Related]

  • 3. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S, Otto SA, Knol GJ, Manting EH, Nanlohy NM, Jansen C, Lange JM, van Oers MH, Miedema F, van Baarle D.
    Eur J Immunol; 2002 Apr 01; 32(4):1080-9. PubMed ID: 11920575
    [Abstract] [Full Text] [Related]

  • 4. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.
    Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D.
    Blood; 2005 Nov 01; 106(9):3166-74. PubMed ID: 16014568
    [Abstract] [Full Text] [Related]

  • 5. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 01; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 6. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection.
    Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K.
    J Immunol; 2003 Mar 01; 170(5):2590-8. PubMed ID: 12594286
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ.
    Semin Cancer Biol; 2008 Dec 01; 18(6):397-408. PubMed ID: 18977445
    [Abstract] [Full Text] [Related]

  • 8. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
    Jansen CA, Piriou E, De Cuyper IM, van Dort K, Lange JM, Miedema F, van Baarle D.
    Antivir Ther; 2006 Dec 01; 11(1):105-16. PubMed ID: 16518966
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.
    Cytotherapy; 2019 Feb 01; 21(2):212-223. PubMed ID: 30396848
    [Abstract] [Full Text] [Related]

  • 10. Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection.
    Legoff J, Amiel C, Calisonni O, Fromentin D, Rajoely B, Abuaf N, Tartour E, Rozenbaum W, Bélec L, Nicolas JC.
    J Clin Immunol; 2004 Mar 01; 24(2):125-34. PubMed ID: 15024179
    [Abstract] [Full Text] [Related]

  • 11. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C, Martin R.
    Brain; 2006 Jun 01; 129(Pt 6):1493-506. PubMed ID: 16569670
    [Abstract] [Full Text] [Related]

  • 12. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.
    Cytometry B Clin Cytom; 2007 Jan 15; 72(1):14-21. PubMed ID: 17041945
    [Abstract] [Full Text] [Related]

  • 13. Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient.
    Piriou ER, van Dort K, Weel JF, Bemelman FJ, Gamadia LE, van Oers MH, van Baarle D.
    Clin Immunol; 2006 Apr 15; 119(1):16-20. PubMed ID: 16386961
    [Abstract] [Full Text] [Related]

  • 14. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R.
    Antivir Ther; 2012 Apr 15; 17(7):1301-9. PubMed ID: 22948290
    [Abstract] [Full Text] [Related]

  • 15. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG, Hirsch HH, Franceschi S, Steffen I, Amari EB, Mueller NJ, Magouras I, Biggar RJ, Rickenbach M, Clifford GM, Swiss HIV Cohort Study.
    AIDS; 2010 Sep 10; 24(14):2245-52. PubMed ID: 20543658
    [Abstract] [Full Text] [Related]

  • 16. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
    Benito JM, López M, Lozano S, Ballesteros C, Martinez P, González-Lahoz J, Soriano V.
    J Acquir Immune Defic Syndr; 2005 Apr 01; 38(4):373-81. PubMed ID: 15764953
    [Abstract] [Full Text] [Related]

  • 17. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ, Xu XQ, Chan KH, Chiang AK.
    Immunology; 2011 Oct 01; 134(2):161-71. PubMed ID: 21896011
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
    O'Sullivan CE, Peng R, Cole KS, Montelaro RC, Sturgeon T, Jenson HB, Ling PD.
    J Med Virol; 2002 Jul 01; 67(3):320-6. PubMed ID: 12116021
    [Abstract] [Full Text] [Related]

  • 19. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus.
    Kang I, Quan T, Nolasco H, Park SH, Hong MS, Crouch J, Pamer EG, Howe JG, Craft J.
    J Immunol; 2004 Jan 15; 172(2):1287-94. PubMed ID: 14707107
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
    Long HM, Leese AM, Chagoury OL, Connerty SR, Quarcoopome J, Quinn LL, Shannon-Lowe C, Rickinson AB.
    J Immunol; 2011 Jul 01; 187(1):92-101. PubMed ID: 21622860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.